Indeed, immunotherapeutic treatment blocking the PD-1-PD-L1 axis has a striking synergistic effect with Mll4 ablation on tumor suppression in immune-competent mice, indicating Mll4 loss could sensitize the refractory tumor cells to anti-PD-1 blockade treatment. The gene discussed is CD274; the disease is neoplasm.